GHENT, BELGIUM--(Marketwire - August 16, 2012) -
GHENT, Belgium, 16 August 2012 - Ablynx [Euronext Brussels: ABLX]
announces its
half-year results will be posted on Wednesday, 22 August 2012 after
market
close.
Dr Edwin Moses, Chairman and CEO of Ablynx, will host a conference call and
live
webcast on the results, followed by a Q&A session on Thursday, 23 August
2012 at
16.00 CET.
To dial into the conference call, please use the following number: +32
(0)2
400 34 63.
Ahead of the call, the results presentation will be made available on
Ablynx's
website, www.ablynx.com. The live webcast can be accessed via the
following
link. Users are recommended to register at least 10 minutes ahead of the
event.
A replay of the webcast will be available on the Company's website
after the
call.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and
development
of Nanobodies®, a novel class of therapeutic proteins based on single-
domain
antibody fragments, for a range of serious human diseases,
including
inflammation, haematology, oncology and pulmonary disease. Today, the
Company
has approximately 25 programmes in the pipeline and seven Nanobodies
are at
clinical development stage. Ablynx has ongoing research
collaborations and
significant partnerships with major pharmaceutical companies,
including
Boehringer Ingelheim, Merck Serono and Novartis. The Company is
headquartered in
Ghent, Belgium. More information can be found on www.ablynx.com.
Press release in pdf format: http://hugin.info/137912/R/1634486/524782.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE
[HUG#1634486]
